title: Novel cardioprotective role of a small heat-shock protein, Hsp20, against ischemia/reperfusion injury.
abstract: BACKGROUND
  Heat-shock proteins (Hsps) have been shown to render cardioprotection from stress-induced injury; however, little is known about the role of another small heat-shock protein, Hsp20, which regulates activities of vasodilation and platelet aggregation, in cardioprotection against ischemia injury. We recently reported that increased expression of Hsp20 in cardiomyocytes was associated with improved contraction and protection against beta-agonist-induced apoptosis.
  
  
  RESULTS
  To investigate whether overexpression of Hsp20 exerts protective effects in both ex vivo and in vivo ischemia/reperfusion (I/R) injury, we generated a transgenic (TG) mouse model with cardiac-specific overexpression of Hsp20 (10-fold). TG and wild-type (WT) hearts were then subjected to global no-flow I/R (45 minutes/120 minutes) using the Langendorff preparation. TG hearts exhibited improved recovery of contractile performance over the whole reperfusion period. This improvement was accompanied by a 2-fold decrease in lactate dehydrogenase released from the TG hearts. The extent of infarction and apoptotic cell death was also significantly decreased, which was associated with increased protein ratio of Bcl-2/Bax and reduced caspase-3 activity in TG hearts. Furthermore, in vivo experiments of 30-minute myocardial ischemia, via coronary artery occlusion, followed by 24-hour reperfusion, showed that the infarct region-to-risk region ratio was 8.1+/-1.1% in TG hearts (n=7), compared with 19.5+/-2.1% in WT hearts (n=11, P<0.001).
  
  
  CONCLUSIONS
  Our data demonstrate that increased Hsp20 expression in the heart protects against I/R injury, resulting in improved recovery of cardiac function and reduced infarction. Thus, Hsp20 may constitute a new therapeutic target for ischemic heart diseases.
authors.affiliation: Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0575, USA.
authors.forename: Guo-Chang
authors.initials: GC
authors.lastname: Fan
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Ren
authors.forename: Jiang
authors.initials: J
authors.lastname: Qian
authors.forename: Qunying
authors.initials: Q
authors.lastname: Yuan
authors.forename: Persoulla
authors.initials: P
authors.lastname: Nicolaou
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: W Keith
authors.initials: WK
authors.lastname: Jones
authors.forename: Guoxiang
authors.initials: G
authors.lastname: Chu
authors.forename: Evangelia G
authors.initials: EG
authors.lastname: Kranias
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015316:Genetic Therapy; D050886:HSP20 Heat-Shock Proteins; D006321:Heart / Q000187:drug effects; D006360:Heat-Shock Proteins / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology*; D066298:In Vitro Techniques; D051379:Mice; D008822:Mice, Transgenic; D009203:Myocardial Infarction / Q000517:prevention & control; D017202:Myocardial Ischemia / Q000188:drug therapy; D010750:Phosphoproteins / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology*; D015424:Reperfusion; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
chemical_list: D002316:Cardiotonic Agents; D050886:HSP20 Heat-Shock Proteins; D006360:Heat-Shock Proteins; D010750:Phosphoproteins